Exploiting inflammation for therapeutic gain in pancreatic cancer von Steele, C W, Jamieson, N B, Evans, T R J, McKay, C J, Sansom, O J, Morton, J P, Carter, C R

Volltext

A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours von Venugopal, B., Awada, A., Evans, T. R. J., Dueland, S., Hendlisz, A., Rasch, W., Hernes, K., Hagen, S., Aamdal, S.

Volltext

Immune checkpoint inhibitors: new strategies to checkmate cancer von Wilson, R. A. M., Evans, T. R. J., Fraser, A. R., Nibbs, R. J. B.

Volltext

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101) von Steele, N. L., Plumb, J. A., Vidal, L., Tjørnelund, J., Knoblauch, P., Buhl-Jensen, P., Molife, R., Brown, R., de Bono, J. S., Evans, T. R. J.

Volltext

A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma von Scott, L. C., Yao, J. C., Benson, A. B., Thomas, A. L., Falk, S., Mena, R. R., Picus, J., Wright, J., Mulcahy, M. F., Ajani, J. A., Evans, T. R. J.

Volltext

A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors von Salazar, R., Jones, R. J., Oaknin, A., Crawford, D., Cuadra, C., Hopkins, C., Gil, M., Coronado, C., Soto-Matos, A., Cullell-Young, M., Iglesias Dios, J. L., Evans, T. R. J.

Volltext

Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours von Lassen, U., Miller, W. H., Hotte, S., Evans, T. R. J., Kollmansberger, C., Adamson, D., Nielsen, D. L., Spicer, J., Chen, E., Meyer, T., Brown, K., Rafi, R., Sawyer, M. B.

Volltext

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database von Cassier, P.A., Polivka, V., Judson, I., Soria, J.-C., Penel, N., Marsoni, S., Verweij, J., Schellens, J.H., Morales-Barrera, R., Schöffski, P., Voest, E.E., Gomez-Roca, C., Evans, T.R.J., Plummer, R., Gallerani, E., Kaye, S.B., Olmos, D.

Volltext

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors von Soria, J.C., Gan, H.K., Blagden, S.P., Plummer, R., Arkenau, H.T., Ranson, M., Evans, T.R.J., Zalcman, G., Bahleda, R., Hollebecque, A., Lemech, C., Dean, E., Brown, J., Gibson, D., Peddareddigari, V., Murray, S., Nebot, N., Mazumdar, J., Swartz, L., Auger, K.R., Fleming, R.A., Singh, R., Millward, M.

Volltext

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours von Macpherson, I.R, Poondru, S, Simon, G.R, Gedrich, R, Brock, K, Hopkins, C.A, Stewart, K, Stephens, A, Evans, T.R.J

Volltext

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours von Boss, D S, Glen, H, Beijnen, J H, Keesen, M, Morrison, R, Tait, B, Copalu, W, Mazur, A, Wanders, J, O'Brien, J P, Schellens, J H M, Evans, T R J

Volltext

Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors von Díaz-Rubio, E., Evans, T. R. J., Tabernero, J., Cassidy, J., Sastre, J., Eatock, M., Bisset, D., Regueiro, P., Baselga, J.

Volltext

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer von Evans, T.R.J., Van Cutsem, E., Moore, M.J., Bazin, I.S., Rosemurgy, A., Bodoky, G., Deplanque, G., Harrison, M., Melichar, B., Pezet, D., Elekes, A., Rock, E., Lin, C., Strauss, L., O’Dwyer, P.J.

Volltext

In vitro evaluation of cancer-specific NF-κB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines von GUO, X, EVANS, T. R. J, SOMANATH, S, ARMESILLA, A. L, DARLING, J. L, SCHATZLEIN, A, CASSIDY, J, WANG, W

Volltext

A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma von Evans, T. R. J., Pentheroudakis, G., Paul, J., McInnes, A., Blackie, R., Raby, N., Morrison, R., Fullarton, G. M., Soukop, M., McDonald, A. C.

Volltext

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors von Milojkovic Kerklaan, B., Slater, S., Flynn, M., Greystoke, A., Witteveen, P. O., Megui-Roelvink, M., de Vos, F., Dean, E., Reyderman, L., Ottesen, L., Ranson, M., Lolkema, M. P. J., Plummer, R., Kristeleit, R., Evans, T. R. J., Schellens, J. H. M.

Volltext

Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response von Scott, L C, Evans, T R J, Cassidy, J, Harden, S, Paul, J, Ullah, R, O'Brien, V, Brown, R

Volltext

A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma von DALHOFF, K, DANCEY, J, SKOV, T, BURCHARTH, F, EVANS, T. R. J, ASTRUP, L, SKOVSGAARD, T, HAMBERG, K. J, LOFTS, F. J, ROSMORDUC, O, ERLINGER, S, BACH HANSEN, J, STEWARD, W. P

Volltext

A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract von Graham, J S, Boyd, K, Coxon, F Y, Wall, L R, Eatock, M M, Maughan, T S, Highley, M, Soulis, E, Harden, S, Bützberger-Zimmerli, P, Evans, T R J

Volltext

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen von JOHNSTON, S. R. D, GUMBRELL, L. A, JONES, A, CANNEY, P, POWLES, T. J, HAYNES, B. P, NUTLEY, B, GRIMSHAW, R, JARMAN, M, HALBERT, G. W, BRAMPTON, M, HAVILAND, J, EVANS, T. R. J, DOWSETT, M, COOMBES, R. C, COLEMAN, R. E, SMITH, I. E, TWELVES, C. J, SOUKOP, M, REA, D. W, EARL, H. M, HOWELL, A

Volltext